A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy

Inclusion Criteria

• •Subject is between the ages of 18 and 75.
• •Subject has a confirmed adenocarcinoma by histology of the prostate.
• •Subject has CAPRA \> 6, or T3 a or b disease on imaging (TRUS and/or MRI), or regional lymphadenopathy suspicious for nodal metastases
• •Subject is scheduled to undergo robotic prostatectomy with extended pelvic lymph node dissection (ePLND) using an da Vinci® X/Xi Surgical System with Firefly® Fluorescent Imaging.
• •Subject is willing and able to provide informed consent
• •Subject is considered capable of complying with study procedures and of understanding a written informed consent document.
• •Subject must be treatment naïve (not having received neo-adjuvant therapy, radiation therapy, hormonal therapy, androgen deprivation therapy within the last 4 months excluding Finasteride, Dutasteride, or other 5 alpha reductase inhibitors, or focal ablation techniques)